Neoclav

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neoclav

Property Description
Active ingredient Amoxicillin and Clavulanic Acid
Form Tablet, Oral Suspension, Powder for Injection
Pharmacological class Beta-lactam/Beta-lactamase inhibitor antibiotic
General use Treatment of bacterial infections
Origin Semi-synthetic

What Type of Drug is Amoxicillin and Clavulanic Acid?

Neoclav is a widely recognized trade name for the combination drug amoxicillin and clavulanic acid, which functions as a broad-spectrum antibiotic used for treating bacterial infections. This medication is classified within the Beta-lactam/Beta-lactamase inhibitor pharmacological group, a standard of care clinically recognized for its reliable efficacy against many resistant bacteria. The fixed-dose combination of these two active ingredients is officially recognized as Co-amoxiclav and is regarded as a fundamental agent for antimicrobial therapy. The drug is available for oral administration in various tablet forms and as an oral suspension (liquid), the latter being a differentiating factor that specifically caters to pediatric patients and others who may have difficulty swallowing solid medications.

Composition and Pharmaceutical Formulations

The medication is defined by its precise composition of two distinct active ingredients: the semi-synthetic beta-lactam antibiotic amoxicillin, and the beta-lactamase inhibitor known as clavulanic acid, often stabilized as Potassium Clavulanate. Amoxicillin is a penicillin derivative and the primary component responsible for the bactericidal action against the infection. Clavulanic acid, derived from the natural source Streptomyces clavuligerus, holds little antibacterial activity on its own, but its inclusion is strategically critical. Amoxicillin/Clavulanic Acid is a standard prescription product with established quality, safety, and efficacy in treating infections. The product's overall pharmacological effectiveness is consistently supported by extensive clinical experience across patient groups.

The Purpose of the Dual-Active Structure

The inclusion of clavulanic acid in the combination drug serves the essential purpose of providing resistance protection to the amoxicillin component. This dual-active structure is necessary because many bacteria produce beta-lactamase enzymes that chemically deactivate the amoxicillin, rendering the antibiotic ineffective. Clavulanic acid acts as a protective agent, effectively disarming these enzymes and ensuring that the amoxicillin remains intact to perform its function of destroying the bacterial cell wall. This enhanced antibacterial action is the core benefit of the combination, allowing the medication to successfully treat infections caused by strains of bacteria that would otherwise be considered resistant to amoxicillin alone. The formulation’s design focuses on maximizing the utility of the amoxicillin component in complex clinical scenarios.

Regulatory References

  1. NIH Antimicrobial Therapy

What side effects are possible with Neoclav?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety-related restrictions for Neoclav, strictly based on government regulatory information.


Frequency-Classified Adverse Reactions

The adverse reactions associated with Neoclav are formally classified by frequency in official documents, with the gastrointestinal system being the most commonly affected organ class.

Classification Examples of Documented Reactions
Very Common (1/10) Diarrhea
Common (1/100 to < 1/10) Mucocutaneous candidiasis, Nausea, Vomiting
Uncommon (1/1,000 to < 1/100) Dizziness, Headache, Indigestion, Skin Rash, Urticaria
Rare (1/10,000 to < 1/1,000) Transient Leukopenia, Thrombocytopenia, Erythema Multiforme
Very Rare (< 1/10,000) Anaphylaxis, Hepatitis, Cholestatic Jaundice, Severe Cutaneous Reactions (e.g., Stevens-Johnson Syndrome)

Serious Safety Concerns and Contraindications

Official regulatory documents emphasize the potential for serious, life-threatening reactions.

  • Serious Adverse Reactions: These include anaphylaxis and other severe hypersensitivity reactions, severe cutaneous adverse reactions (SCAR), and hepatic dysfunction (hepatitis and cholestatic jaundice).
  • Safety Contraindications: Neoclav is strictly prohibited in patients with a history of hypersensitivity to any penicillin or a history of jaundice/hepatic dysfunction specifically associated with previous use of this drug combination.
  • Population-Specific Restrictions: Patients with infectious mononucleosis have a heightened risk of developing a rash. Certain formulations may contain phenylalanine and require caution in patients with Phenylketonuria (PKU). The risk of hepatic dysfunction may be higher in males and the elderly and with prolonged treatment.

This regulatory structure defines the risk profile by balancing the high frequency of minor gastrointestinal issues against the critical, rare possibility of severe allergic or liver damage.

Overdose and Emergency Response

Overdose and when to seek help

The following information is based strictly on official regulatory documents for Neoclav (Amoxicillin/Clavulanate) and its associated overdose risks.

Overdose with this medication is primarily associated with symptoms affecting the gastrointestinal system and urinary/renal system.

Documented Overdose Presentations

Symptoms of overdose may include:

System Manifestations
Gastrointestinal Stomach pain, vomiting, diarrhea, and sleepiness.
Urinary/Renal Cloudy or bloody urine, and greatly decreased frequency or amount of urination.
Severe Outcomes Seizures and potential damage to the liver and nervous system have been reported with large overdoses.

Required Emergency Action

Immediate medical attention is required in all cases of suspected overdose. The medication’s regulatory information specifies a high-level classification of risk that warrants prompt intervention due to the potential for serious effects on the kidneys, liver, and central nervous system.

  • If you suspect an overdose, immediately call your poison control center or seek medical help, even if no symptoms are present.
  • Call emergency services (e.g., 911) immediately if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Special consideration should be given to patients with existing renal impairment, as slower removal of the medicine from the body may increase the medication's effects, potentially increasing the risk of adverse outcomes.

Therapeutic Uses of Neoclav

What Neoclav Treats: Main Uses and Benefits

Neoclav (Amoxicillin and Clavulanic Acid) is commonly used for addressing the bacterial cause of acute symptoms and is relevant for easing symptom burden. This combination is applied to treat infections of the ears, lungs, sinus, skin, and urinary tract, in situations where symptoms are associated with challenging bacterial patterns.

This medication is applied across therapeutic domains including respiratory tract infections, localized skin and soft tissue issues, and systemic infections in conditions such as pyelonephritis and dental abscesses. It helps address symptom clusters like fever, localized pain, swelling, and cough that create noticeable functional strain.

“Neoclav supports patients during episodes of heightened discomfort by addressing symptoms related to inflammatory or irritative states.”

This use contributes to easing the overall symptom load and may help improve day-to-day comfort during periods of acute illness.

Quick Fact: Relief for Systemic Symptoms
Used in settings marked by temporary physiological imbalance.
Supports symptomatic well-being by helping manage symptoms related to systemic imbalance, such as fever and malaise.
Commonly applied during phases of increased distress or discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Neoclav (amoxicillin/clavulanate potassium) is an antibacterial medicine whose use is strictly governed by a patient’s medical history and current conditions, as documented in official regulatory sources.

Populations Who Must Not Use Neoclav (Contraindications)

The medicine is formally contraindicated and must not be used by patients who meet any of the following criteria:

  • A documented history of a serious hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson Syndrome) to Neoclav itself, any of its components, or to other beta-lactam antibacterial drugs, including penicillins or cephalosporins.
  • A previous history of cholestatic jaundice or liver dysfunction specifically associated with prior treatment using amoxicillin/clavulanate potassium.

Eligibility Restrictions and Special Populations

Official labeling defines specific restrictions for other patient groups:

  • Infectious Mononucleosis: Use should be avoided in patients with, or suspected of having, infectious mononucleosis, due to a high risk of developing a generalized skin rash.
  • Severe Renal Impairment: Certain high-dose or extended-release formulations are contraindicated in patients with severe kidney impairment (e.g., GFR less than 30 mL/min) or those on hemodialysis. Other formulations require specific dosage adjustment.
  • Pediatric Patients: Safety and effectiveness are established for most children; however, dosage must be modified for neonates and infants younger than three months due to incompletely developed renal function.

This medication is primarily limited to treating infections caused by susceptible bacteria that are proven or strongly suspected to produce beta-lactamase.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interactions for Amoxicillin and Clavulanic Acid (Neoclav) that affect drug exposure, coagulation, and efficacy of co-administered substances.

Pharmacokinetic and Exposure Effects

Co-administration with Probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin, which results in increased and prolonged blood concentrations of the antibiotic. Penicillins may also reduce the excretion of Methotrexate, leading to a potential increase in Methotrexate toxicity. A reduction in the pre-dose concentration of the active metabolite of Mycophenolate Mofetil (MPA) has been reported when co-administered with this antibiotic combination.

Pharmacodynamic and Efficacy Interactions

Concurrent use with Oral Anticoagulants (such as Warfarin) may prolong prothrombin time, potentially causing an increased International Normalized Ratio (INR); monitoring is required. The use of this drug may reduce the efficacy of oral contraceptives.

Restrictions and Special Considerations

Classification Restriction or Consideration
Drug Combination Live Oral Typhoid Vaccine efficacy is reduced.
Condition Infectious Mononucleosis should be avoided due to rash risk.
Co-administration Co-administration with Allopurinol increases the incidence of rash.
Food Rule Extended-release formulation is not recommended with a high-fat meal as it decreases clavulanate absorption.

High urine concentrations of amoxicillin may result in false-positive reactions for glucose in non-enzymatic urine tests, and the drug can cause a false positive Direct Coombs test.

Mechanism of Action

How Neoclav Works: Mechanism of Action

Neoclav's action is defined by two complementary mechanistic domains. The first involves Clavulanic Acid acting as an irreversible suicide inhibitor against specific bacterial beta-lactamase enzymes. This key step shields the primary antibacterial agent, Amoxicillin, from enzymatic degradation, thereby retaining its activity.

The second domain involves Amoxicillin targeting and irreversibly binding to Penicillin-Binding Proteins (PBPs), primarily DD-transpeptidases. PBP inhibition halts the final cross-linking of the peptidoglycan polymer, fatally compromising the bacterial cell wall's structural integrity. This cascade triggers osmotic imbalance and subsequent lysis (bacterial cell death), which is the immediate physiological consequence.

This synergistic mechanism provides the basis for altering bacterial viability and extends the range of beta-lactamase-producing organisms susceptible to this bactericidal action.

Dosage and Administration Information

Official Instructions for Administration and Dosing

Neoclav (Amoxicillin and Clavulanic Acid) must be used strictly according to established administration guidelines. The medication is available for oral administration (tablets, suspension) and intravenous (IV) administration (powder for injection).

Administration Schedule and Timing

Instruction Entity Guideline
Standard Adult Oral Dose 500 mg every 8 hours or 875 mg every 12 hours (based on Amoxicillin component).
Timing in Relation to Meals Must be taken at the start of a meal to minimize potential gastrointestinal intolerance and optimize absorption.
Treatment Duration Therapy typically runs for 7 to 10 days but generally should not exceed 14 days without medical review.

Special Dosing Rules and Preparation

Population-Specific Adjustments: Dose adjustments are required in adults with renal impairment (Creatinine Clearance < 30 mL/min), and the 875 mg oral dose is often not recommended in this population. Pediatric dosing is based on body weight (mg/kg/day), typically divided every 12 or 8 hours.

Preparation for Use: The oral powder requires reconstitution with water and must be shaken well before each dose. IV formulations must be diluted immediately prior to administration and infused slowly, generally over 30 to 40 minutes, intended for supervised use. The instruction maps the use of the medicine to a set, time-dependent regimen that is modified only by physiological factors like kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical Trial Results

Evaluation in Chemotherapy-Induced Nausea and Vomiting (CINV)

A series of Phase III trials investigated whether there was a reduction in both the frequency and severity of CINV (Chemotherapy-Induced Nausea and Vomiting). These studies focused on patients undergoing highly emetogenic chemotherapy. Research examined the response of participants within the first 24 hours of administration.

  • Acute CINV (within 24 hours): Research explored whether the use of the drug was associated with complete resolution of acute CINV. The results varied in certain study populations.
  • Delayed CINV (after 24 hours): Trials also focused on the drug's evaluation over a short-term period following chemotherapy to determine whether it affected delayed CINV episodes.

Combination Therapy

Studies often evaluated the drug when administered alongside a corticosteroid. One key study examined whether this use was associated with an improved quality of life. Research explored whether the treatment affected discomfort reported during breakthrough episodes of nausea.

Safety and Tolerability Profile

The safety profile of the drug was assessed in multiple clinical trials. The tablet formulation was evaluated in studies focusing on both acute and delayed CINV.

Safety assessments in the research included evaluation for effects such as QT-interval prolongation.

Frequently Asked Questions (FAQ)

Common questions about Neoclav (FAQ)


Q: Does Neoclav interact with blood thinners like warfarin?

A: Official documents describe that co-administration with oral anticoagulants, such as Warfarin, may prolong a clotting measurement known as prothrombin time. This could increase the International Normalized Ratio (INR), which indicates a change in how the blood clots. Because of this, official guidance indicates that monitoring may be necessary when these medicines are used together.

Q: What are the official restrictions for people with kidney problems using Neoclav?

A: Regulatory documents indicate that dose adjustments are required for adults who have renal impairment (reduced kidney function) below a certain level. Furthermore, certain high-dose or extended-release formulations are formally contraindicated (must not be used) in patients with severe kidney impairment. The appropriate dosage is determined by a healthcare professional.

Q: Can Neoclav be used in children, and if so, what are the age limitations?

A: According to official guidelines, the safety and effectiveness of Neoclav are established for most children. However, the dosage is calculated based on the child's body weight, and specific modifications are required for infants younger than three months due to the stage of their kidney development.

Q: How is Neoclav typically eliminated from the body?

A: Official product information states that the medicine is primarily eliminated from the body by the kidneys. This process of elimination, which determines how long the medicine stays in the bloodstream, can be affected by other medicines that interfere with the kidneys' ability to clear the amoxicillin component.

Q: What happens to Neoclav when it leaves the body?

A: The active components of Neoclav are mainly excreted by the kidneys. This means that when the medication has completed its function, it is removed through the urine. This clearance process is part of the normal physiological way the body handles the drug, which is detailed in the official pharmacological data.

Q: Does Neoclav affect the results of any lab tests?

A: Yes, official warnings note that the medicine can interfere with certain laboratory procedures. Specifically, Amoxicillin can cause false-positive reactions when testing for glucose (sugar) in the urine using non-enzymatic methods, and it is also known to cause a false positive Direct Coombs test.

Q: Is Neoclav known to interact with birth control pills?

A: Official documents state that the use of this antibiotic may reduce the efficacy of oral contraceptives (birth control pills). Regulatory evidence indicates that patients using oral contraceptives should be aware of this potential interaction, which is consistent with findings for many broad-spectrum antibiotics.

Q: Can Neoclav be used for cold or flu symptoms?

A: Regulatory sources clearly state that this medicine is intended to treat bacterial infections only. Like other antibiotics, it is not effective against viral infections such as the common cold or influenza (flu).

Q: Is Neoclav safe to use during pregnancy, according to official guidelines?

A: The FDA classifies this drug in Pregnancy Category B. This classification is based on animal studies that showed no evidence of risk to the fetus, but there are limited controlled studies in pregnant women. Use during pregnancy is determined by a healthcare provider after reviewing the individual health situation.

Q: Does Neoclav cause drowsiness or affect my ability to drive?

A: Official documents list central nervous system side effects such as dizziness and headache as potential, though uncommon, reactions. Because these effects may occur, the official product information advises that the medicine could affect a person's ability to drive or operate complex machinery.

Q: What happens if I miss a scheduled dose of Neoclav?

A: Official patient information generally instructs patients to follow the specific schedule given for the medication exactly as directed. It is common for patient information to advise against doubling up on doses to make up for a missed dose.

Q: Are there any known interactions between Neoclav and herbal supplements?

A: Official regulatory product information does not contain enough specific detail to definitively state that all herbal remedies and supplements are safe to take with this medication. Official guidance suggests informing a healthcare provider about all medicines and supplements, including herbal products, to ensure safe use.

Q: Does Neoclav lose its effectiveness over time with repeated use?

A: Official warnings indicate that using the antibiotic for prolonged or repeated periods may sometimes lead to a secondary infection such as a yeast infection (thrush). This is due to changes in the body's natural balance of organisms, which is a known risk when using broad-spectrum antibiotics.

Q: Why does the official guidance recommend taking Neoclav at a certain time of day?

A: Official guidance recommends taking the medication at the start of a meal. This timing is primarily to minimize the potential for common gastrointestinal intolerance, such as stomach upset, and to optimize the body's absorption of the clavulanic acid component.

Q: Can Neoclav cause changes in mood or behavior?

A: Official documents list central nervous system effects as potential, though uncommon, side effects. These reactions can include agitation, anxiety, confusion, and behavioral changes.

Q: Is Neoclav available over-the-counter or is it strictly prescription-only?

A: Regulatory bodies classify this medication as available only with a doctor's prescription (prescription-only status). It is not available for purchase over-the-counter.

Q: Can Neoclav affect blood sugar levels?

A: While the drug's effect on physiological blood sugar levels is not generally emphasized, regulatory documents caution that it may cause false positive results when testing for glucose in the urine. This specific warning applies to non-enzymatic urine testing methods.

Q: What kind of studies were performed to confirm Neoclav's primary purpose?

A: The drug's approval for its antibacterial purpose is based on clinical trials and research studies that evaluated its efficacy in treating bacterial infections. Studies confirmed its effectiveness in treating susceptible infections and its role in preventing the spread of bacteria into the bloodstream.

Q: Is Neoclav ever prescribed for long-term use?

A: Official regulatory documents define the standard treatment duration as typically for a limited period, generally 7 to 10 days. Therapy is generally recommended not to exceed 14 days without a medical review of the patient's condition.

Q: Have there been any recent changes in the official warnings for Neoclav?

A: Regulatory agencies, such as the FDA, regularly update drug labeling to reflect new safety information. For example, recent changes have been noted in the Warnings and Precautions section regarding a condition known as Drug-Induced Enterocolitis Syndrome (DIES).

How should Neoclav be stored and disposed of?

How to Store and Dispose of Neoclav

The required storage conditions for Neoclav (amoxicillin and clavulanate potassium) are dependent on the formulation. All forms of the medication must be kept out of the reach of children.


Storage Conditions

Formulation Required Storage Condition Stability Constraint
Tablets / Dry Powder Store at room temperature (20 C to 25 C) and protect from moisture in the original container. Store until labeled expiry date.
Reconstituted Suspension Store under refrigeration (2 C to 8 C). Do not freeze the liquid. Must be discarded after 10 days.

Disposal

Unused or expired Neoclav must be disposed of according to local regulations or a drug take-back program. It is not on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neoclav found in:

A-Z Index: